Breast Cancer | Specialty

Litton Talks Talazoparib in BRCA1/2+ Advanced Breast Cancer

July 21st 2020

Jennifer Litton, MD, discusses findings from the phase 3 EMBRACA trial on talazoparib in patients with advanced BRCA1/2-positive breast cancer.

Daniel Osman, Founder of Miami Breast Cancer Conference, Dies

July 18th 2020

Daniel A. Osman, MD, a South Florida surgeon who founded the Miami Breast Cancer Conference® and helped shepherd its growth into a premier medical meeting, died peacefully in Weston, Florida, on July 15 at the age of 98.

Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Cancer

July 17th 2020

Angela DeMichele, MD, MSCE, shares how to utilize available data with CDK4/6 inhibitors in the neoadjuvant and adjuvant settings to optimize outcomes for patients with hormone receptor–positive breast cancer.

Key Data Inform Treatment Decisions in Early HER2+ Breast Cancer

July 17th 2020

The growing number of treatments within the HER2-positive breast cancer armamentarium signals a need to redefine and tailor neoadjuvant and adjuvant strategies to individual patients.

Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach

July 17th 2020

The optimal sequence of therapies for patients with metastatic HER2-positive breast cancer must be an individualized one, and should be dependent on the presence and/or level of central nervous system disease.

Dr. Czerniecki on the Importance of Multidisciplinary Efforts for Breast Cancer Brain/CNS Metastases

July 16th 2020

Brian Czerniecki, MD, PhD, discusses the importance of utilizing a multidisciplinary effort to treat patients with breast cancer who develop brain or central nervous system metastases.

Trastuzumab Deruxtecan Shows “Remarkable” Responses in HER2+ Breast Cancer, Requires Monitoring of Respiratory Symptoms

July 16th 2020

Charles E. Geyer, Jr, MD, discusses the state of HER2-positive breast cancer, the significance of the results of the DESTINY-Breast01 trial, and symptoms that could be an early indicator of interstitial lung disease.

Adjuvant T-DM1/Pertuzumab Combo Misses iDFS End Point in High-Risk HER2-Positive Breast Cancer

July 16th 2020

Anthracycline-based chemotherapy followed by ado-trastuzumab emtansine plus pertuzumab did not show statistically significant or clinically meaningful improvement in invasive disease-free survival in patients with high-risk HER2-positive early breast cancer, missing the primary end point of the phase 3 KAITLIN trial.

Han Highlights the Need for Personalized Treatment in HER2+ Early-Stage Breast Cancer

July 15th 2020

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Dr. Ahmed on Key Strategies for Managing Breast Cancer Brain Metastases

July 15th 2020

Kamran A. Ahmed, MD, discusses key strategies to manage patients with breast cancer and brain metastases.

Sam Shares Strategies for Providing Optimal Care to Geriatric Patients With Cancer During the COVID-19 Crisis

July 14th 2020

Christine Sam, MD, discusses strategies to prevent the spread of COVID-19 in geriatric patients with cancer and shared advice on how to overcome unique challenges faced in the care of this population.

Notable ASCO Trial Updates

July 14th 2020

HER2+ MBC Adverse-Event Management

July 14th 2020

After Progression on PIK3CAi Therapy: MTOR Inhibition

July 14th 2020

Significance of PIK3CA Mutation in HR+ Breast Cancer

July 14th 2020

Mechanisms of Resistance to CDK4/6 Inhibitors

July 14th 2020

CDK4/6 Meta-Analysis Data

July 14th 2020

CDK4/6 Clinical Trial Survival Data Impact

July 14th 2020

CDK4/6 Inhibition in HR+ Metastatic Breast Cancer

July 14th 2020

Next-Generation Sequencing: Triple Negative Breast Cancer

July 14th 2020